TECHNOLOGY FOR THE MANUFACTURE OF SARS-COV-2 BIOBLOCK NASAL AND THROAT SPRAY BASED ON ANTIBODIES AGAINST SARS-COV-2 CORONA VIRUS WAS DEVELOPED AND PATENTED IN COOPERATION BETWEEN COMPANIES AND UNIVERS -- MEDICA - World Forum for Medicine

28.09.2021

Chemi-Pharm AS

TECHNOLOGY FOR THE MANUFACTURE OF SARS-COV-2 BIOBLOCK NASAL AND THROAT SPRAY BASED ON ANTIBODIES AGAINST SARS-COV-2 CORONA VIRUS WAS DEVELOPED AND PATENTED IN COOPERATION BETWEEN COMPANIES AND UNIVERS

CONSORTIUM IN THE COMPOSITION: ICOSAGENI GRUPP, AS CHEMI-PHARM, OÜ TEADUS JA TEGU, ESTONIAN UNIVERSITY OF LIFE SCIENCES AND THE UNIVERSITY OF TARTU DEVELOPED AND PATENTED TECHNOLOGY FOR THE MANUFACTURE OF NASAL AND THROAT SPRAY SARS-COV-2 BIOBLOCK BASED ON ANTIBODIES AGAINST CORONAVIRUS SARS-COV-2.

In cooperation with Estonian companies and universities, a technology was developed that can be used to prepare a nasal and throat spray based on antibodies against SARS-CoV-2, which during initial research has shown its effectiveness in preventing coronavirus infection.

According to Professor Mart Ustav, who led the development of the new technology, their work is based on a preparation made from colostrum from hyperimmunized cows. “Colostrum has the best natural role in providing the newborn with primary protective immunity through antibodies produced by the mother’s body. For our part, we have developed a technology for purifying colostrum antibodies, which results in a preparation that can be used to make a nasal and throat spray, which in turn has the effect of preventing coronavirus infection,” Professor Ustav explained the positive effects of a novel product in the fight against coronavirus. Professor Ustav emphasized that it was not a drug but an antiviral preparation that works on the surface of the mucous membranes in the nasopharynx, where it can specifically inactivate the Covid-19 virus SARS CoV-2.

According to Prof. Ustav, preclinical tests have shown that the product produced had SARS CoV-2 virus-neutralizing activity. “We emphasize that these antibodies were effective not only against the virus strain that originated in Wuhan but also against new, more prevalent virus variants of Great Britain, South Africa, and Brazil, which we studied in biochemical as well as pseudovirus infection experiments. Animal experiments had shown that by instilling a solution of colostrum-derived antibodies in the nose one hour before infection with high levels of SARS-CoV-2, our preparation was able to significantly reduce the viral titer in the lungs. This indicates that the developed nasal and throat spray preparation is able to trap and neutralize the SARS-CoV-2 virus in the nasopharynx,” specified Prof. Ustav.

According to Ruth Oltjer, one of the leaders of the endeavor, the head of AS Chemi-Pharm, it is important to move quickly further from research. “The next step is for the consortium to conduct clinical trials and start producing SARS-CoV-2 BioBlock nasal and throat sprays containing the preparation as soon as possible,” Oltjer added. To this end, we have launched the production of SARS-CoV-2 BioBlock test batches and have submitted the protocols of the two clinical trials to the Research Ethics Committee of the University of Tartu for approval. These studies confirm the results of preclinical trials and provide a basis for the use of antiviral nasal spray as a prophylactic tool in the control of an extensive corona pandemic.

Ruth Oltjer added that the SARS-CoV-2 BioBlock could be helpful wherever social distancing is difficult: at homes, in restaurants, at schools, in sports practices, at sports competitions, at workplaces, in vehicles, and other crowded places. “It would be especially advisable to use the product on people that are in close contact with infected people, in order to reduce the risk of infection, as well as on infected people, so that these people would be less infectious to their loved ones,” Oltjer said, emphasizing that the SARS-CoV-2 BioBlock nasal and throat spray is not a substitute for vaccination or wearing a mask, but an additional measure to break the infection chains of the virus.

The consortium that developed the new technology includes Icosagen Grupp, AS Chemi-Pharm, University of Tartu (Institute of Pharmacy, Institute of Biomedical and Transitional Medicine and Institute of Technology), Estonian University of Life Sciences (Institute of Veterinary Medicine and OÜ Eerika farm), and OÜ Teadus ja Tegu.

Responsible composition of the consortium: Mart Ustav (Icosagen Group, mart.ustav@icosagen.com), Ruth Oltjer (AS ChemiPharm, ruth@chemi-pharm.com), Väino Poikalainen (OÜ Teadus ja Tegu, vaino.poikalainen@gmail.com), Toomas Tiirats (EULS, toomas.tiirats@emu.ee), Mario Plaas (UT, mario.plaas@ut.ee), Karin Kogermann (UT, karin.kogermann@ut.ee), Eva Zušinaite (UT, eva.zushinaite@ut.ee)

Exhibitor Data Sheet